In last trading session, Unity Biotechnology Inc (NASDAQ:UBX) saw 0.73 million shares changing hands with its beta currently measuring 0.78. Company’s recent per share price level of $1.79 trading at $0.46 or 34.59% at ring of the bell on the day assigns it a market valuation of $30.16M. That closing price of UBX’s stock is at a discount of -12.85% from its 52-week high price of $2.02 and is indicating a premium of 47.49% from its 52-week low price of $0.94. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.36 million shares which gives us an average trading volume of 122.97K if we extend that period to 3-months.
For Unity Biotechnology Inc (UBX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.43 in the current quarter.
Unity Biotechnology Inc (NASDAQ:UBX) trade information
Upright in the green during last session for gaining 34.59%, in the last five days UBX remained trading in the green while hitting it’s week-highest on Tuesday, 01/07/25 when the stock touched $1.79 price level, adding 9.6% to its value on the day. Unity Biotechnology Inc’s shares saw a change of 83.33% in year-to-date performance and have moved 57.02% in past 5-day. Unity Biotechnology Inc (NASDAQ:UBX) showed a performance of 49.17% in past 30-days. Number of shares sold short was 0.25 million shares which calculate 3.3 days to cover the short interests.
Unity Biotechnology Inc (UBX) estimates and forecasts
Statistics highlight that Unity Biotechnology Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 21.77% of value to its shares in past 6 months, showing an annual growth rate of 45.62% while that of industry is 16.50. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 36.93% during past 5 years.
Unity Biotechnology Inc (NASDAQ:UBX)’s Major holders
Insiders are in possession of 1.31% of company’s total shares while institution are holding 20.55 percent of that, with stock having share float percentage of 20.82%. Investors also watch the number of corporate investors in a company very closely, which is 20.55% institutions for Unity Biotechnology Inc that are currently holding shares of the company.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 395.99 shares of worth $0.71 million or 2.35% of the total outstanding shares. The later fund manager was in possession of 194.78 shares on Sep 30, 2024 , making its stake of worth around $0.35 million in the company or a holder of 1.16% of company’s stock.
